These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 31624747)

  • 1. Treatment of laryngopharyngeal reflux disease: A systematic review.
    Lechien JR; Mouawad F; Barillari MR; Nacci A; Khoddami SM; Enver N; Raghunandhan SK; Calvo-Henriquez C; Eun YG; Saussez S
    World J Clin Cases; 2019 Oct; 7(19):2995-3011. PubMed ID: 31624747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. pH Impedance and high-resolution manometry in laryngopharyngeal reflux disease high-dose proton pump inhibitor failures.
    Carroll TL; Fedore LW; Aldahlawi MM
    Laryngoscope; 2012 Nov; 122(11):2473-81. PubMed ID: 22965767
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of acids, pepsin, bile acids, and trypsin on laryngopharyngeal reflux diseases: physiopathology and therapeutic targets.
    Li Y; Xu G; Zhou B; Tang Y; Liu X; Wu Y; Wang Y; Kong J; Xu T; He C; Zhu S; Wang X; Zhang J
    Eur Arch Otorhinolaryngol; 2022 Jun; 279(6):2743-2752. PubMed ID: 34860271
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Double-blind, placebo-controlled study with alginate suspension for laryngopharyngeal reflux disease.
    Tseng WH; Tseng PH; Wu JF; Hsu YC; Lee TY; Ni YH; Wang HP; Hsiao TY; Hsu WC
    Laryngoscope; 2018 Oct; 128(10):2252-2260. PubMed ID: 29399800
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Weaning of proton pump inhibitors in patients with suspected laryngopharyngeal reflux disease.
    Lin RJ; Sridharan S; Smith LJ; Young VN; Rosen CA
    Laryngoscope; 2018 Jan; 128(1):133-137. PubMed ID: 28730666
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Laryngopharyngeal Reflux Disease and Gastroesophageal Reflux Disease Can Mutually Influence.
    Wang X; Zhang J; Wang J; Liu Z; Zhang C; Zhao J; Zou S; Ma X; Li J
    J Voice; 2022 Nov; ():. PubMed ID: 36347736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine, and placebo: evidence from randomized clinical trials.
    Caro JJ; Salas M; Ward A
    Clin Ther; 2001 Jul; 23(7):998-1017. PubMed ID: 11519776
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of nonacid reflux in laryngopharyngeal reflux diseases.
    Li J; Wang J; Wu M; Zhao J; Guo H
    Eur Arch Otorhinolaryngol; 2020 Oct; 277(10):2813-2819. PubMed ID: 32390084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systematic review: proton pump inhibitors (PPIs) for the healing of reflux oesophagitis - a comparison of esomeprazole with other PPIs.
    Edwards SJ; Lind T; Lundell L
    Aliment Pharmacol Ther; 2006 Sep; 24(5):743-50. PubMed ID: 16918878
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Correlation analysis between Dx-pH monitoring and proton pump inhibitor test in the diagnosis of laryngopharyngeal reflux disease].
    Chen ZL; Wu HW; Mei XW; Yin WH; Xu SY; Liu SQ; Chen YC; Wang G; Zhang CJ; Ding XL; Wu JN
    Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2020 Jan; 55(1):34-39. PubMed ID: 31954386
    [No Abstract]   [Full Text] [Related]  

  • 11. LPR: how different diagnostic tools shape the outcomes of treatment.
    Wan Y; Yan Y; Ma F; Wang L; Lu P; Maytag A; Jiang JJ
    J Voice; 2014 May; 28(3):362-8. PubMed ID: 24491501
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rethinking the laryngopharyngeal reflux treatment algorithm: Evaluating an alternate empiric dosing regimen and considering up-front, pH-impedance, and manometry testing to minimize cost in treating suspect laryngopharyngeal reflux disease.
    Carroll TL; Werner A; Nahikian K; Dezube A; Roth DF
    Laryngoscope; 2017 Oct; 127 Suppl 6():S1-S13. PubMed ID: 28842999
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms.
    Röhss K; Lind T; Wilder-Smith C
    Eur J Clin Pharmacol; 2004 Oct; 60(8):531-9. PubMed ID: 15349707
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How many cases of laryngopharyngeal reflux suspected by laryngoscopy are gastroesophageal reflux disease-related?
    de Bortoli N; Nacci A; Savarino E; Martinucci I; Bellini M; Fattori B; Ceccarelli L; Costa F; Mumolo MG; Ricchiuti A; Savarino V; Berrettini S; Marchi S
    World J Gastroenterol; 2012 Aug; 18(32):4363-70. PubMed ID: 22969200
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of Proton Pump Inhibitors in Laryngopharyngeal Reflux: Clinical Evaluation in a North Indian Population.
    Bhargava A; Faiz SM; Srivastava MR; Shakeel M; Singh NJ
    Indian J Otolaryngol Head Neck Surg; 2019 Sep; 71(3):371-377. PubMed ID: 31559206
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological treatment of children with gastro-oesophageal reflux.
    Tighe M; Afzal NA; Bevan A; Hayen A; Munro A; Beattie RM
    Cochrane Database Syst Rev; 2014 Nov; 2014(11):CD008550. PubMed ID: 25419906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities.
    Li XQ; Andersson TB; Ahlström M; Weidolf L
    Drug Metab Dispos; 2004 Aug; 32(8):821-7. PubMed ID: 15258107
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation and management of laryngopharyngeal reflux.
    Ford CN
    JAMA; 2005 Sep; 294(12):1534-40. PubMed ID: 16189367
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Twice-daily dosing of esomeprazole effectively inhibits acid secretion in CYP2C19 rapid metabolisers compared with twice-daily omeprazole, rabeprazole or lansoprazole.
    Sahara S; Sugimoto M; Uotani T; Ichikawa H; Yamade M; Iwaizumi M; Yamada T; Osawa S; Sugimoto K; Umemura K; Miyajima H; Furuta T
    Aliment Pharmacol Ther; 2013 Nov; 38(9):1129-37. PubMed ID: 24099474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of proton pump inhibitors in patients with laryngopharyngeal reflux disease.
    Chiba T; Kudara N; Abiko Y; Endo M; Suzuki K; Sugai T; Ishijima K; Fukuda K; Yamazaki K; Sato H
    Hepatogastroenterology; 2011; 58(110-111):1580-2. PubMed ID: 21940324
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.